-
Mashup Score: 3Upfront - 12 day(s) ago
Studies have shown upregulation of other VEGF subtypes when VEGF-A is blocked. This has led to several companies targeting VEGF-C and VEGF-D to improve outcomes in retinal vascular diseases.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 1Glaucoma Research Foundation Awards $2.5 Million in Grants - 12 day(s) ago
“This is the largest annual research budget in our 46-year history,” said Thomas M. Brunner, GRF President and CEO, in a news release.
Source: www.glaucomaphysician.netCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 6Uveitis Corner - 14 day(s) ago
Long-term results can help guide clinicians’ treatment choices.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 5Clinical Trial Update - 15 day(s) ago
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 6Gene Therapy for Wet Age-related Macular Degeneration - 16 day(s) ago
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 1Broader VEGF Pathway Inhibition for Wet AMD - 17 day(s) ago
VEGF-C and VEGF-D are innately involved in the neovascular etiology, so treating that component, in addition to traditional anti-VEGF-A treatment, may have the potential for improved VA.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 10Retinal Physician and the Entire Retina Community Mourn the Passing of Dr. Ramin Tadayoni - 17 day(s) ago
Dr. Tadayoni was well known internationally for his leadership in retinal surgery and ophthalmic education, and he was a revered mentor and friend.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 0
Atsena Therapeutics has announced that dosing has begun for the second cohort in LIGHTHOUSE, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201, a gene therapy intended to treat X-linked retinoschisis.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 2Subspecialty News - 19 day(s) ago
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 20Polymeric Technologies for Retinal Drug Delivery - 21 day(s) ago
Polymeric technologies have the potential to revolutionize the intravitreal treatment approach for retinal diseases.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
Innovations in #VEGF Inhibition Delivery: Companies are targeting VEGF-C in their therapeutic pipelines. By Peter K. Kaiser, MD https://t.co/s8LwcXoEJ5 #ophthalmology https://t.co/pdX4maLfPC